Department of Oncology, The Affiliated Hospital of Southwest Medical University, Luzhou, China.
Nuclear Medicine and Molecular Imaging Key Laboratory of Sichuan Province, Luzhou, China.
Front Immunol. 2022 Aug 8;13:970879. doi: 10.3389/fimmu.2022.970879. eCollection 2022.
Symptomatic colon metastasis from primary lung cancer is rare in clinical practice. We report the case of a 58-year-old patient with advanced lung adenocarcinoma who developed abdominal symptoms, including abdominal distention and difficulty defecating, after immunotherapy and chemotherapy. The patient was diagnosed with lung adenocarcinoma, and systemic positron emission tomography-computed tomography confirmed multiple lymph node, pleural, and adrenal metastases. Molecular detection indicated BRAF V600E mutation and high programmed death-ligand 1 (PD-L1) expression. After first-line anti-programmed cell death protein 1 immunotherapy combined with chemotherapy, the nodes in the chest remarkably diminished. However, it was followed by colon obstruction, incomplete ileus, and bone metastasis. Endoscopic histological examination confirmed adenocarcinoma but could not identify primary or secondary tumors due to insufficient tissue. We performed colon resection to remove the obstruction, and postoperative tissue pathological microscopy confirmed metastasis from the lung adenocarcinoma. We corroborated the BRAF V600E mutation and high PD-L1 expression and supported the molecular features of lung adenocarcinoma. During hospitalization, the patient presented with unbearable pain in the bone metastases, and palliative radiotherapy was administered. Then, the patient received dabrafenib plus trametinib as the second-line therapy. This report discusses the clinical characteristics, pathology, imaging, molecular profile assessments, and treatment of primary lung adenocarcinoma with colon metastasis.
原发性肺癌的结肠转移在临床上较为罕见。我们报告了一例 58 岁的晚期肺腺癌患者,该患者在免疫治疗和化疗后出现腹部症状,包括腹胀和排便困难。该患者被诊断为肺腺癌,全身正电子发射断层扫描-计算机断层扫描证实存在多个淋巴结、胸膜和肾上腺转移。分子检测显示 BRAF V600E 突变和高程序性死亡配体 1(PD-L1)表达。一线抗程序性死亡蛋白 1 免疫治疗联合化疗后,胸部淋巴结显著减少。但随后出现结肠梗阻、不完全肠梗阻和骨转移。内镜组织学检查证实为腺癌,但由于组织不足,无法确定原发性或继发性肿瘤。我们进行了结肠切除术以解除梗阻,术后组织病理显微镜检查证实为肺腺癌转移。我们证实了 BRAF V600E 突变和高 PD-L1 表达,并支持肺腺癌的分子特征。住院期间,该患者出现骨转移引起的难以忍受的疼痛,给予姑息性放疗。然后,患者接受了达布拉非尼加曲美替尼作为二线治疗。本报告讨论了原发性肺腺癌伴结肠转移的临床特征、病理学、影像学、分子谱评估和治疗。